| Drug Name |
Maribavir |
| Drug ID |
BADD_D02571 |
| Description |
Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.[L39322] Most standard CMV therapies, such as [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to DNA polymerase-based therapies, and their use is often limited by toxicities like myelosuppression and renal injury.[A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections.
Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients.[L39327] |
| Indications and Usage |
Maribavir is indicated for the treatment of adult and pediatric patients (weighing >35kg and at least 12 years old) with post-transplant cytomegalovirus (CMV) infection which is refractory to standard treatment with [ganciclovir], [valganciclovir], [cidofovir], or [foscarnet].[L39322] |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AX10 |
| DrugBank ID |
DB06234
|
| KEGG ID |
D04859
|
| MeSH ID |
C400401
|
| PubChem ID |
471161
|
| TTD Drug ID |
D07WXI
|
| NDC Product Code |
64764-800; 58567-106 |
| UNII |
PTB4X93HE1
|
| Synonyms |
maribavir | benzimidavir | 5,6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosylbenzimidazole | 1263W94 | 1263-W-94 | GW 1263 | GW-1263 | BW 1263W94 | BW-1263W94 | GW 257406X | GW257406X | GW-257406X |
